OPTIMER PHARMACEUTICALS INC 4
4 · OPTIMER PHARMACEUTICALS INC · Filed Oct 28, 2013
Insider Transaction Report
Form 4
Schaum Meredith
Gen.Counsel and Chief Comp Off
Transactions
- Disposition to Issuer
Common stock
2013-10-24$10.75/sh−2,937$31,573→ 0 total - Disposition to Issuer
Stock option (right to buy)
2013-10-24$2.06/sh−30,000$61,800→ 0 totalExercise: $10.72Exp: 2023-02-26→ Common stock (30,000 underlying)
Footnotes (3)
- [F1]Includes 1,148 shares acquired under the Optimer Pharmaceuticals, Inc. ("Optimer") employee stock purchase plan on October 22, 2013.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of July 30, 2013 (the "Merger Agreement"), among Optimer, Cubist Pharmaceuticals, Inc. ("Cubist"), and PDRS Corporation, shares were converted into the right to receive per share consideration of: (i) $10.75 cash and (ii) one contingent value right issued by Cubist in accordance with the Contingent Value Rights Agreement, dated as of October 24, 2013, between Cubist and American Stock Transfer & Trust Company, LLC (together, the "Per Share Merger Consideration").
- [F3]Pursuant to the terms of the Merger Agreement, each option was fully vested and converted into the right to receive a cash payment equal to the excess, if any, of $12.78 (the last reported sale price of a share of Optimer common stock on The NASDAQ Global Select Market on October 23, 2013) over such option's per share exercise price.